Galecto Inc
NASDAQ:GLTO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Galecto Inc
Income from Continuing Operations
Galecto Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galecto Inc
NASDAQ:GLTO
|
Income from Continuing Operations
-$21.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Income from Continuing Operations
kr963m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
24%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Income from Continuing Operations
kr6.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Income from Continuing Operations
-€228m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-21%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Income from Continuing Operations
kr1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
|
Saniona AB
STO:SANION
|
Income from Continuing Operations
kr284.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Galecto Inc
Glance View
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
See Also
What is Galecto Inc's Income from Continuing Operations?
Income from Continuing Operations
-21.4m
USD
Based on the financial report for Dec 31, 2024, Galecto Inc's Income from Continuing Operations amounts to -21.4m USD.
What is Galecto Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
10%
Over the last year, the Income from Continuing Operations growth was 44%. The average annual Income from Continuing Operations growth rates for Galecto Inc have been 25% over the past three years , 10% over the past five years .
